ClinicalTrials.gg
CompletedNCT05135871Updated Jul 25, 2024Results posted

Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects

A Phase 1 interventional study of Mavacamten in Hypertrophic Cardiomyopathy, sponsored by LianBio LLC. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-25.

Sponsored by LianBio LLC · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Enrollment
16th of 21
45 · median 75
Started
2021
the only one that year
Phase 1
5 of 21
none open now
Registered
9th of 21
by date
Lead sponsor
2 of 21
LianBio LLC

Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 16th largest by enrollment, is the only one that started in 2021, is one of 5 in phase 1, and was the 9th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

Mavacamten is a small-molecule allosteric inhibitor of cardiac myosin that reversibly inhibits its binding to cardiac actin, thereby relieving systolic hypercontractility and improving ventricular compliance. This is an open-label, parallel-group, single-center Phase 1 clinical study. Healthy adult Chinese subjects with different genotypes will be included and administered with a single fasted oral dose of mavacamten to evaluate its PK profile. Up to 44 subjects will be enrolled in this study.

Read the detailed description

Approximately 44 healthy adult Chinese subjects are expected to be enrolled in this study according to their genotypes into 4 cohorts.

The doses administered include: 15 mg for cohort 1; 25 mg for Cohort 2; 15 mg for Cohort 3; 15 mg for Cohort 4. Blood samples will be collected from subjects at scheduled time points for PK testing. Series of safety assessments (including but not limited to AEs, laboratory tests, vital signs, and ECGs) will be performed during the whole study at specified time points.

This study will consist of the following 5 periods:

  • Pre-screening period and Screening period (Day -43 to Day -2, up to 42 days)
  • In-house period (Day -1 to Day 3, total 4 days)
  • Outpatient period (Day 4 to Day 75, total 72 days):
  • End of study visit (Day 75)
03

Conditions studied

  • Hypertrophic Cardiomyopathy

Keywords

  • Mavacamten
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Male or female between the ages of 18 and 60 (inclusive) at screening
  • With a (BMI) between 18 kg/m2 and 30 kg/m2 (inclusive) at screening
  • Healthy as determined at screening and on Day -1
  • Female subjects shall not be pregnant or breastfeeding
  • Male partners of female subjects must also adopt a method from screening through 5 months after administration of the drug
  • Able to understand and comply with the study procedures, understand the risks involved in this study, and provide written according to local and institutional guidelines before screening procedure

Key Exclusion Criteria:

  • History of arrhythmia
  • History of any type of malignant tumors within 5 years of the Screening Visit
  • Positive serologic tests at screening for infections with (HIV) antibody, virus (HCV) antibody or virus (HBV) surface antigen at screening
  • The vital signs of screening period and Day -1 were unqualified
  • Subjects who have taken prescription medications within 28 days prior to screening or within 5 times of T1/2 (if known), whichever is longer
  • History or evidence of any other clinically significant abnormalities, conditions, or diseases that, in the opinion of the investigator, would pose a risk to the safety of the subject or interfere with study evaluation, procedures, or its completion
  • Any condition or treatment for a condition that might interfere with the conduct of the trial or might, in the opinion of the investigator, put the subject at risk, including but not limited to, alcoholism, drug dependence or abuse, and psychiatric conditions, if he/she participates in this study
  • Positive test for alcohol or drug abuse at screening and on Day -1
  • Use of tobacco within 28 days prior to screening
  • to mavacamten or any of the components of its formulation
  • Prior exposure to mavacamten
  • Unable to comply with the study restrictions/requirements, including the number of required visits to the clinical site
  • Unsuitable to participate in the study as judged by the investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Cohort 1: Mavacamten 15 mg

    Cohort 1: 15 mg capsules × 1 on Day 1

    Drug: Mavacamten

  • Experimental
    Cohort 2: Mavacamten 25 mg

    Cohort 2: 10 mg capsules x 1 and 15 mg capsules x 1 on Day 1

    Drug: Mavacamten

  • Experimental
    Cohort 3: Mavacamten 15 mg

    Cohort 3: 15 mg capsules × 1 on Day 1

    Drug: Mavacamten

  • Experimental
    Cohort 4: Mavacamten 15 mg

    Cohort 4: 15 mg capsules × 1 on Day 1

    Drug: Mavacamten

Interventions

  • Single fasted oral dose of Mavacamten 15/25 mg on Day 1

    Also known as: Mavacamten capsule

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) (0-last), AUC(0-inf)

    Determination of pharmacokinetics parameters as measured by area under curve AUC(0-last), AUC(0-inf)

    Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose

  2. Maximum Concentration (Cmax)

    Determination of pharmacokinetics parameters as measured by maximum concentration (Cmax)

    Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose

  3. Time to Maximum Concentration (Tmax)

    Determination of pharmacokinetics parameters as measured by time to maximum concentration (Tmax)

    Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose

  4. Elimination Half-life (T1⁄2)

    Determination of pharmacokinetics parameters as measured by elimination half-life (T1⁄2)

    Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose

  5. Apparent Volume of Distribution (Vd/F)

    Determination of pharmacokinetics parameters as measured by apparent volume of distribution (Vd/F)

    Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose

  6. Apparent Clearance (CL/F)

    Determination of pharmacokinetics parameters as measured by apparent clearance (CL/F)

    Time frame: Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose

Secondary outcomes

  1. Number of Participants With Adverse Events

    Safety assessments will be performed by incidence of adverse events during the whole study at specified time points

    Time frame: Up to 75 days

  2. Body Weight at Screening and EOS

    Safety assessments will be performed by vital signs during the whole study at screening, Day-1, Day 3 and at the EOS Visit. A complete physical examination includes assessments of general appearance, skin, head and neck, chest, abdomen, back, spine, extremity neurological, and mental systems. Brief physical examination means chest examinations. Height (cm) and body weight (kg) will be measured at screening, and BMI (kg/m2) will be calculated. Body weight (kg) will be measured at EOS. The mean weight and the standard deviation are analysis for different cohort.

    Time frame: Body weight (kg) will be measured at screening (baseline) and EOS(75 days).

  3. Physical Examination Findings

    Safety assessments will be performed by physical examination findings during the whole study at specified time points

    Time frame: Up to 75 days

  4. Heart Rate at Baseline and Day 75

    Safety assessments will be performed by electrocardiogram (ECG) parameters findings during the whole study at specified time points

    Time frame: Up to 75 days

  5. Clinical Laboratory Tests Data

    Safety assessments will be performed by clinical laboratory tests data(including hematology and blood chemistry, coagulation and urinalysis parameters) during the whole study at specified time points

    Time frame: Up to 75 days

07

Results

Posted Jul 25, 2024
Limitations and caveats
There are no special limitations and caveats to this trial.

Participant flow

Participant flow — Overall Study
MilestoneCohort 2: Mavacamten 25 mgCohort 1: Mavacamten 15 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Started1312128
Completed1212128
Not completed1000
Withdrew: 1 subject withdrew from the study before administration of the imp due to pre-dose abnormal ecg1000

Outcome measures

PrimaryArea Under the Curve (AUC) (0-last), AUC(0-inf)

Determination of pharmacokinetics parameters as measured by area under curve AUC(0-last), AUC(0-inf)

Time frame:
Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Reported as:
Geometric mean · h*ng/mL
Area Under the Curve (AUC) (0-last), AUC(0-inf)
h*ng/mLCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
(AUC) (0-last)9956 ± 35.6120040 ± 50.4918270 ± 21.0539980 ± 23.60
AUC(0-inf)10030 ± 35.4420280 ± 52.4718430 ± 21.1845810 ± 25.51
PrimaryMaximum Concentration (Cmax)

Determination of pharmacokinetics parameters as measured by maximum concentration (Cmax)

Time frame:
Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax)
ng/mLCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Maximum Concentration (Cmax)395.4 ± 39.95571.8 ± 25.69485.2 ± 34.96435.7 ± 35.66
PrimaryTime to Maximum Concentration (Tmax)

Determination of pharmacokinetics parameters as measured by time to maximum concentration (Tmax)

Time frame:
Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Reported as:
Median · h
Time to Maximum Concentration (Tmax)
hCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Time to Maximum Concentration (Tmax)0.88 (0.50 to 3.00)1.50 (0.50 to 4.00)0.75 (0.50 to 3.00)0.63 (0.33 to 1.00)
PrimaryElimination Half-life (T1⁄2)

Determination of pharmacokinetics parameters as measured by elimination half-life (T1⁄2)

Time frame:
Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Reported as:
Geometric mean · h
Elimination Half-life (T1⁄2)
hCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Elimination Half-life (T1⁄2)120.3 ± 23.44143.6 ± 42.32205.4 ± 22.31572.0 ± 25.03
PrimaryApparent Volume of Distribution (Vd/F)

Determination of pharmacokinetics parameters as measured by apparent volume of distribution (Vd/F)

Time frame:
Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Reported as:
Geometric mean · mL
Apparent Volume of Distribution (Vd/F)
mLCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Apparent Volume of Distribution (Vd/F)259500 ± 29.93255300 ± 16.60241200 ± 23.13270200 ± 26.95
PrimaryApparent Clearance (CL/F)

Determination of pharmacokinetics parameters as measured by apparent clearance (CL/F)

Time frame:
Predose, Day 1, Day 7, Day 10, Day 14, Day 21, Day 28, Day 35, Day 45, Day 67 and Day 75 post-dose
Reported as:
Geometric mean · mL/h
Apparent Clearance (CL/F)
mL/hCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Apparent Clearance (CL/F)1495 ± 35.441233 ± 52.47814.0 ± 21.18327.5 ± 25.51
SecondaryNumber of Participants With Adverse Events

Safety assessments will be performed by incidence of adverse events during the whole study at specified time points

Time frame:
Up to 75 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Number of subjects with at least 1 AE3693
Number of subjects with at least 1 TEAE3693
Worst severity of TEAE(Mild)3683
Worst severity of TEAE(Moderate)0010
Worst severity of TEAE(Severe)0000
Drug-related TEAEs0101
TESAE0000
TEAE leading to study discontinuation0000
TEAE leading to death0000
AESI0000
SecondaryBody Weight at Screening and EOS

Safety assessments will be performed by vital signs during the whole study at screening, Day-1, Day 3 and at the EOS Visit. A complete physical examination includes assessments of general appearance, skin, head and neck, chest, abdomen, back, spine, extremity neurological, and mental systems. Brief physical examination means chest examinations. Height (cm) and body weight (kg) will be measured at screening, and BMI (kg/m2) will be calculated. Body weight (kg) will be measured at EOS. The mean weight and the standard deviation are analysis for different cohort.

Time frame:
Body weight (kg) will be measured at screening (baseline) and EOS(75 days).
Reported as:
Mean · kg
Body Weight at Screening and EOS
kgCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Change from Baseline0.80 ± 2.8990.70 ± 1.738-0.36 ± 2.3781.25 ± 2.184
Baseline69.41 ± 12.69962.78 ± 8.45865.89 ± 11.15768.26 ± 11.147
Day 7570.21 ± 13.08863.48 ± 9.40565.53 ± 10.92969.51 ± 11.530
SecondaryPhysical Examination Findings

Safety assessments will be performed by physical examination findings during the whole study at specified time points

Time frame:
Up to 75 days
Reported as:
Number · participants
Physical Examination Findings
participantsCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Number of abnormal but not clinically significant comprehensive physical examinations in baseline5242
Number of abnormal but not clinically significant comprehensive physical examinations in Day 755242
The number of abnormal with clinically significant comprehensive physical examinations in Day 750100
SecondaryHeart Rate at Baseline and Day 75

Safety assessments will be performed by electrocardiogram (ECG) parameters findings during the whole study at specified time points

Time frame:
Up to 75 days
Reported as:
Mean · beats/min
Heart Rate at Baseline and Day 75
beats/minCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Heart Rate-Baseline63.3 ± 8.7063.0 ± 10.4463.3 ± 10.4462.8 ± 9.27
Heart Rate-D7564.8 ± 7.1266.4 ± 7.8867.5 ± 5.3566.8 ± 7.17
SecondaryClinical Laboratory Tests Data

Safety assessments will be performed by clinical laboratory tests data(including hematology and blood chemistry, coagulation and urinalysis parameters) during the whole study at specified time points

Time frame:
Up to 75 days
Reported as:
Number · participants
Clinical Laboratory Tests Data
participantsCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Blood fibrinogen increased0011
White blood cell count decreased0101
Alanine aminotransferase increased0010
Neutrophil count increased0010
Neutrophil count decreased0001
Eosinophil percentage increased0010
Eosinophil count increased0010
Urobilinogen urine increased0001
White blood cell count increased0100
Hemoglobin decreased0001

Adverse events

Collected over The study took about 80 days to monitor the adverse event for each subject.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Mavacamten 15 mg0/12 (0%)0/12 (0%)3/12 (25%)
Cohort 2: Mavacamten 25 mg0/12 (0%)0/12 (0%)6/12 (50%)
Cohort 3: Mavacamten 15 mg0/12 (0%)0/12 (0%)9/12 (75%)
Cohort 4: Mavacamten 15 mg0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventCohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mg
Upper respiratory tract infectionInfections and infestations2/123/123/121/8
Chest painGeneral disorders0/122/121/120/8
Blood fibrinogen increasedInvestigations0/122/121/120/8
White blood cell count decreasedInvestigations0/121/120/121/8
Neutrophil count decreasedInvestigations0/120/120/121/8
Urobilinogen urine increasedInvestigations0/120/120/121/8
Hemoglobin decreasedInvestigations0/120/120/121/8
Oral herpesInfections and infestations0/120/121/120/8
GastroenteritisInfections and infestations0/120/121/120/8
AppendicitisInfections and infestations0/121/120/120/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mgTotal
Mean26.8 ± 4.9931.0 ± 7.1228.9 ± 6.3235.4 ± 4.3130.1 ± 6.44
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mgTotal
Female333211
Male999633
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mgTotal
Chinese121212844
Non-Chinese00000
Han121212844
Non-Han00000
Region of Enrollment
Region of Enrollment(participants)Cohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mgTotal
China121212844
Body mass index
Body mass index(kg/m^2)Cohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mgTotal
Mean24.34 ± 2.44423.82 ± 2.57123.26 ± 2.43423.04 ± 2.31223.67 ± 2.421
CYP2C19 genotype
CYP2C19 genotype(Participants)Cohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mgTotal
Ultra-rapid metabolizer00000
Rapid metabolizer11002
Normal metabolizer11110022
Intermediate metabolizer0012012
Poor metabolizer00088
Left ventricular ejection fraction(%)
Left ventricular ejection fraction(%)(%)Cohort 1: Mavacamten 15 mgCohort 2: Mavacamten 25 mgCohort 3: Mavacamten 15 mgCohort 4: Mavacamten 15 mgTotal
Mean68.0 ± 5.0366.9 ± 39666.4 ± 3.9964.0 ± 5.5866.5 ± 4.63
08

Study locations

1 site
  • Huashan Hospital Fudan University
    Shanghai, Shanghai 200040, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Feb 2022, 3 months.

Results were first posted in Jul 2024, 2 years 5 months after primary completion.

Of 12 phase 1 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2021
First posted
Nov 26, 2021
StartActual
Oct 31, 2021
Primary completionActual
Feb 5, 2022
CompletionActual
Feb 28, 2022
Results first posted
Jul 25, 2024
Last update
Jul 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05135871
Lead sponsor
LianBio LLC
Responsible party
Sponsor
First posted
Nov 26, 2021
Start date
Oct 31, 2021
Primary completion
Feb 5, 2022
Completion
Feb 28, 2022
Results posted
Jul 25, 2024
Last update
Jul 25, 2024

Study contacts

Jing Zhang, Doctor
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion